Nasdaq · Healthcare
CASTLE BIOSCIENCES INC (CSTL)
As-reported financials and recent SEC filings for CASTLE BIOSCIENCES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$344.2M
Net income
$-24.2M
Net margin
-7.0%
Diluted EPS
$-0.83
ROE
-5.1%
P/E (TTM)
—
Market cap
$737.0M
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M |
| Operating income | $-42.8M | $8.7M | $-68.0M | $-72.9M | $-40.1M |
| Net income | $-24.2M | $18.2M | $-57.5M | $-67.1M | $-31.3M |
| Diluted EPS | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-03
View on EDGAR →1442026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →Go deeper on CSTL
Search CASTLE BIOSCIENCES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.